X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1540) 1540
prostate cancer (1533) 1533
male (1464) 1464
abiraterone (1443) 1443
abiraterone acetate (1238) 1238
oncology (1111) 1111
enzalutamide (990) 990
docetaxel (744) 744
chemotherapy (712) 712
prostatic neoplasms, castration-resistant - drug therapy (689) 689
increased survival (644) 644
urology & nephrology (639) 639
metastasis (570) 570
cancer (504) 504
androgen receptor (464) 464
aged (457) 457
survival (446) 446
prostatic neoplasms, castration-resistant - pathology (417) 417
prostatic neoplasms - drug therapy (407) 407
castration (397) 397
treatment outcome (391) 391
middle aged (389) 389
antineoplastic agents - therapeutic use (379) 379
androgens (377) 377
care and treatment (377) 377
castration-resistant prostate cancer (374) 374
men (360) 360
double-blind (343) 343
prednisone (334) 334
phenylthiohydantoin - analogs & derivatives (319) 319
antitumor-activity (310) 310
therapy (300) 300
prostate (298) 298
prostatic neoplasms - pathology (289) 289
mitoxantrone (279) 279
aged, 80 and over (278) 278
cabazitaxel (259) 259
neoplasm metastasis (241) 241
receptors, androgen - metabolism (241) 241
animals (235) 235
pharmacology & pharmacy (234) 234
urology (234) 234
androgen antagonists - therapeutic use (230) 230
metastases (230) 230
research (226) 226
mitoxantrone plus prednisone (225) 225
taxoids - therapeutic use (210) 210
survival analysis (205) 205
antineoplastic combined chemotherapy protocols - therapeutic use (204) 204
cancer therapies (204) 204
phenylthiohydantoin - therapeutic use (204) 204
analysis (203) 203
disease-free survival (198) 198
patients (198) 198
prognosis (198) 198
expression (197) 197
drug therapy (196) 196
plus prednisone (196) 196
disease progression (195) 195
progression (187) 187
receptors, androgen - genetics (184) 184
cell line, tumor (180) 180
retrospective studies (171) 171
prostate-specific antigen - blood (169) 169
testosterone (169) 169
endocrinology & metabolism (168) 168
health aspects (164) 164
resistance (164) 164
resistant prostate-cancer (164) 164
medicine & public health (161) 161
androgen-deprivation therapy (158) 158
metastatic castration-resistant prostate cancer (158) 158
orchiectomy (154) 154
prostatic neoplasms, castration-resistant - blood (154) 154
drug resistance, neoplasm (153) 153
development and progression (151) 151
androgen deprivation therapy (150) 150
trial (148) 148
clinical trials (147) 147
prostatic neoplasms - metabolism (147) 147
prostatic neoplasms, castration-resistant - mortality (147) 147
prostatic neoplasms, castration-resistant - metabolism (145) 145
immunotherapy (143) 143
antineoplastic agents, hormonal - therapeutic use (142) 142
sipuleucel-t (140) 140
prostatic neoplasms, castration-resistant - genetics (137) 137
antiandrogen (136) 136
open-label (133) 133
urologic and male genital diseases (129) 129
cyp17 (128) 128
androstenes (126) 126
steroid 17-alpha-hydroxylase - antagonists & inhibitors (126) 126
tumors (123) 123
biochemistry & molecular biology (121) 121
abiraterone acetate - therapeutic use (119) 119
hematology, oncology and palliative medicine (118) 118
prostate-specific antigen (118) 118
bone neoplasms - secondary (116) 116
prostatic neoplasms - therapy (116) 116
androstenes - therapeutic use (114) 114
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2413) 2413
German (86) 86
French (70) 70
Spanish (37) 37
Russian (31) 31
Hungarian (8) 8
Czech (6) 6
Japanese (6) 6
Dutch (3) 3
Chinese (2) 2
Italian (2) 2
Portuguese (2) 2
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 4, pp. 338 - 351
Journal Article
Annals of oncology, ISSN 0923-7534, 2018, Volume 29, Issue 5, pp. 1235 - 1248
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 4, pp. 352 - 360
The addition of abiraterone, a drug that blocks endogenous androgen synthesis, to standard androgen-deprivation therapy in patients with newly diagnosed,... 
ANDROGEN-DEPRIVATION THERAPY | MEDICINE, GENERAL & INTERNAL | RECOMMENDATIONS | PLACEBO-CONTROLLED PHASE-3 | SURVIVAL ANALYSIS | CLINICAL-TRIALS | DOUBLE-BLIND | LEUPROLIDE ACETATE | DOCETAXEL | CHEMOTHERAPY | NEOADJUVANT | Prednisolone - adverse effects | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prostatic Neoplasms - radiotherapy | Prednisolone - administration & dosage | Prostatic Neoplasms - surgery | Humans | Middle Aged | Abiraterone Acetate - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Prostatic Neoplasms - mortality | Abiraterone Acetate - administration & dosage | Neoplasm Metastasis - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged, 80 and over | Androgen Antagonists - therapeutic use | Adult | Aged | Androgen Antagonists - administration & dosage | Androgen Antagonists - adverse effects | Prostatic Neoplasms - drug therapy | Androgen suppression therapy | Usage | Prednisone | Research | Prostate cancer | Medical research | Prostate-specific antigen | Clinical trials | Metastasis | Patients | Cancer therapies | Metastases | Androgens | Chemotherapy | Pain | Castration | Medical prognosis | Hypokalemia | Death | Prostate | Abiraterone Acetate/administration & dosage | Prednisolone/administration & dosage | Androgen Antagonists/administration & dosage | Medical and Health Sciences | Medicin och hälsovetenskap | Neoplasm Metastasis/drug therapy | Steroid 17-alpha-Hydroxylase/antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols/adverse effects | Klinisk medicin | Clinical Medicine | Prostatic Neoplasms/drug therapy | Cancer and Oncology | Cancer och onkologi
Journal Article
Nature (London), ISSN 1476-4687, 2016, Volume 533, Issue 7604, pp. 547 - 551
Abiraterone blocks androgen synthesis and prolongs survival in patients with castration-resistant prostate cancer, which is otherwise driven by intratumoral... 
ACTIVATION | CYP17A1 INHIBITION | RAT | MULTIDISCIPLINARY SCIENCES | ANDROGEN-RECEPTOR | BIOLOGY | MEN | RESISTANCE | STEROID 5-ALPHA-REDUCTASE | DIHYDROTESTOSTERONE | DEHYDROGENASE | Physiological aspects | Prostate cancer | Care and treatment | Enzymes | Androgens | Metabolites | Oxidation | Metabolism | Gene expression | Steroids
Journal Article
European Urology, ISSN 0302-2838, 2014, Volume 68, Issue 1, pp. 147 - 153
Journal Article
Journal of clinical pharmacology, ISSN 0091-2700, 2015, Volume 55, Issue 12, pp. 1406 - 1414
Journal Article
Journal Article
Annals of oncology, ISSN 0923-7534, 2018, Volume 29, Issue 5, pp. 1249 - 1257
Journal Article
European Urology, ISSN 0302-2838, 2016, Volume 70, Issue 5, pp. 718 - 721
Abstract Coadministration of docetaxel and abiraterone acetate plus prednisone (AA + P) may benefit patients with metastatic castration-resistant prostate... 
Urology | Metastatic castration-resistant prostate cancer | Toxicity | Abiraterone acetate | Combination | Androgen receptor | Docetaxel | Safety | Drug-drug interaction | Pharmacokinetics | prostate cancer | UROLOGY & NEPHROLOGY | Metastatic castration-resistant | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Drug Monitoring - methods | Prostatic Neoplasms, Castration-Resistant - pathology | Dose-Response Relationship, Drug | Abiraterone Acetate - administration & dosage | Neoplasm Metastasis | Antineoplastic Agents - adverse effects | Antineoplastic Agents - pharmacokinetics | Abiraterone Acetate - pharmacokinetics | Taxoids - adverse effects | Prednisone - administration & dosage | Prednisone - adverse effects | Prostatic Neoplasms, Castration-Resistant - blood | Abiraterone Acetate - adverse effects | Antineoplastic Combined Chemotherapy Protocols | Treatment Outcome | Prostatic Neoplasms, Castration-Resistant - drug therapy | Disease Progression | Prostate-Specific Antigen - blood | Taxoids - pharmacokinetics | Disease-Free Survival | Taxoids - administration & dosage | Prednisone - pharmacokinetics | Aged | Neoplasm Staging | Medical research | Care and treatment | Chemotherapy | Corticosteroids | Medicine, Experimental | Prednisone | Metastasis | Prostate cancer | Acetates | Cancer | Steroids
Journal Article
BMC Cancer, ISSN 1471-2407, 04/2015, Volume 15, Issue 1, p. 222
Journal Article